Urine Metabolites of Suspected Community-Acquired Pneumonia - Summary - MDSpire

Urine Metabolites of Suspected Community-Acquired Pneumonia

  • By

  • Lilliam Ambroggio

  • Todd A Florin

  • Kayla Williamson

  • Grace Bosma

  • Brandie D Wagner

  • Larisa Yeomans

  • Jae Hyun Kim

  • Heidi Sucharew

  • Maurizio Macaluso

  • Richard M Ruddy

  • Kathleen A Stringer

  • Samir S Shah

  • February 12, 2025

  • 0 min

Share

Objective:

To identify urinary metabolites associated with suspected community-acquired pneumonia (CAP) in children compared to healthy controls.

Key Findings:
  • 253 case patients and 122 controls were included in the study.
  • The metabolite-only model had an AUC of 0.97, while the combination model had an AUC of 0.99.
  • Key discriminating metabolites included 2-aminobutyrate, fumarate, hypoxanthine, acetone, leucine, quinolinate, valine, O-acetylcarnitine, citrate, trigonelline, 4-hydroxybenzoate, isoleucine, carnitine, 2-hydroxyisovalerate, betaine, and succinate.
  • The combined model included additional clinical factors and metabolites, enhancing diagnostic accuracy.
Interpretation:

Urine metabolite concentrations can effectively distinguish healthy children from those with suspected CAP, potentially improving diagnostic accuracy over traditional methods.

Limitations:
  • The study was limited to a specific age range (3 months to 12 years).
  • Further validation of identified metabolites is needed in external cohorts and diverse populations.
Conclusion:

Metabolomics offers a promising noninvasive diagnostic tool for differentiating CAP in children, which may address limitations of current diagnostic approaches.

Original Source(s)

Urine Metabolites of Suspected Community-Acquired Pneumonia

  • by Lilliam Ambroggio, Todd A Florin, Kayla Williamson, Grace Bosma, Brandie D Wagner, Larisa Yeomans, Jae Hyun Kim, Heidi Sucharew, Maurizio Macaluso, Richard M Ruddy, Kathleen A Stringer, Samir S Shah

  • February 12, 2025

Related Content

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

The aging scientific workforce collides with rising fabricating citations in medical journals

Antibiotic Falls Short in Disc-Related Back Pain

A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.